Cathie Wood stocks have been foundering for the past few months owing to volatile market conditions caused in-part by aggressive Federal Reserve interest rate hikes. So, given their companies’ bleak...

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single...

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing...

Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell...

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused...

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022,...